Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery


ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery

Author(s): Qiang Fu, Jin Sun, Wenping Zhang, Xiaofan Sui, Zhongtian Yan and Zhonggui He

Volume 4, Issue 3, 2009

Page: [262 - 272] Pages: 11

DOI: 10.2174/157489209789206869

Price: $65


Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab™) paclitaxel (nab-paclitaxel; Abraxane®) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nabtechnology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.

Keywords: Nab- technology, anti-cancer drug, paclitaxel, albumin

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy